BiotechTube

Gonal -f® [r-hFSH] + Ovitrelle® [r-hCG alfa] + Gonadotropin-releasing hormone (GnRH) Agonist + Gonadotropin-releasing hormone (GnRH) Antagonist

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

In Vitro Fertilization

Conditions

In Vitro Fertilization

Trial Timeline

Aug 1, 2008 → Aug 1, 2010

NCT ID
NCT01210144

About Gonal -f® [r-hFSH] + Ovitrelle® [r-hCG alfa] + Gonadotropin-releasing hormone (GnRH) Agonist + Gonadotropin-releasing hormone (GnRH) Antagonist

Gonal -f® [r-hFSH] + Ovitrelle® [r-hCG alfa] + Gonadotropin-releasing hormone (GnRH) Agonist + Gonadotropin-releasing hormone (GnRH) Antagonist is a approved stage product being developed by Merck for In Vitro Fertilization. The current trial status is terminated. This product is registered under clinical trial identifier NCT01210144. Target conditions include In Vitro Fertilization.

What happened to similar drugs?

0 of 3 similar drugs in In Vitro Fertilization were approved

Approved (0) Terminated (0) Active (3)
🔄COL-1620 + Gonadotropin-releasing hormone (GnRH) analogue + Follicle-stimulating hormone (FSH) + Human Chorionic Gonadotropin (hCG)MerckPhase 3
🔄Corifollitropin alfa + RecFSH / Follitropin beta (Days 1 to 7) + Placebo Corifollitropin alfa + Placebo RecFSH / follitropin beta + RecFSH / Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + ProgesteroneOrganonPhase 3
🔄Corifollitropin alfa + FSH + GnRH antagonist + (rec)hCG + ProgesteroneOrganonPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01210144ApprovedTerminated

Competing Products

8 competing products in In Vitro Fertilization

See all competitors
ProductCompanyStageHype Score
COL-1620 + Gonadotropin-releasing hormone (GnRH) analogue + Follicle-stimulating hormone (FSH) + Human Chorionic Gonadotropin (hCG)MerckPhase 3
40
Follitropin betaOrganonPre-clinical
20
150 µg Corifollitropin Alfa + 200 IU RecFSH/Follitropin beta (Days 1 to 7) + Placebo for Corifollitropin Alfa + Placebo for RecFSH/Follitropin beta + 200 IU RecFSH/Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + ProgesteroneOrganonPre-clinical
20
Corifollitropin alfa + RecFSH / Follitropin beta (Days 1 to 7) + Placebo Corifollitropin alfa + Placebo RecFSH / follitropin beta + RecFSH / Follitropin beta (Days 8 to hCG) + Ganirelix + hCG + ProgesteroneOrganonPhase 3
34
corifollitropin alfa + recFSH (follitropin alfa) + gonadatropin releasing hormone (GnRH) antagonist ganirelix + human chorion gonadatropin (hCG) + progesterone + placebo-recFSH (follitropin alfa) + placebo-corifollitropin alfa + open-label recFSHOrganonPre-clinical
20
Org 36286 (corifollitropin alfa)OrganonPhase 2
29
OrgalutranOrganonPre-clinical
20
Corifollitropin alfa + FSH + GnRH antagonist + (rec)hCG + ProgesteroneOrganonPhase 3
34